OrthoPediatrics will distribute CERAMENT bone void filler to pediatric hospitals within the United States.

OssDsign will launch a U.S. clinical registry to collect real-world data on Catalyst in spinal fusion applications.

The expanded FDA clearance applies to indications for use with NuVasive's thoracolumbar spinal interbody portfolio.

OrthogenRx has developed GenVisc and TriVisc viscosupplementation products to treat OA knee pain.

NuVasive Specialized Orthopedics will supply the STIMULAN orthobiologic calcium matrix in Germany.

Gross proceeds will advance Bone Therapeutics' lead orthopedic asset, ALLOB, through mid-stage clinical development for bone regeneration.

Link Health will have global rights for development, manufacturing and commercialization of ALLOB allogeneic bone cell therapy.

Funds will support development of a fibroblast-based cell therapy platform with application in orthopedics and disc degeneration.

Biologics4Life is developing a injectable synthetic bone graft materials, complementing Graftys' resorbable calcium phosphate cement.

The combined company will operate as a pure-play regenerative medicine and orthopedics company, serving hospital, ASC and office care settings.